Trial · NCT02684851
The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery
NCT02684851, Phase 3, Completed, Wake Forest University Health Sciences; results first posted 2021-01-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery. Trials, record NCT02684851. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02684851
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery
- NCT number
- NCT02684851
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 87 participants, actual
- Lead sponsor
- Wake Forest University Health Sciences
- Conditions
- Acetabular Fractures
- Interventions
- Tranexamic Acid, Placebo
- First posted
- 2016-02-18
- Last updated
- 2022-04-21
- Results first posted
- 2021-01-19
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Allogenic Blood Transfusion Rates | post-operative | Number of participant received allogenic blood transfusions. |
| Primary | Units of Packed Red Blood Cells Transfused | perioperative | Average units packed red blood cells transfused among participants |
| Secondary | Number of Participants With a Thromboembolic Event | 30 days | Do patients undergoing acetabular ORIF who receive tranexamic acid have a higher risk for thromboembolic events than patients who receive placebo? |
| Secondary | Estimate Blood Loss | perioperative | To measure average estimate perioperative blood loss |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Allogenic Blood Transfusion Rates | post-operative | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Units of Packed Red Blood Cells Transfused | perioperative | Units of packed red blood cells | MEAN | |
| SECONDARY | Number of Participants With a Thromboembolic Event | 30 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Estimate Blood Loss | perioperative | mL | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Allogenic Blood Transfusion Rates | Tranexamic | 21 | Participants | ||
| Allogenic Blood Transfusion Rates | Placebo | 13 | Participants | ||
| Units of Packed Red Blood Cells Transfused | Tranexamic | 2.65 | Standard Deviation 1.27 | Units of packed red blood cells | |
| Units of Packed Red Blood Cells Transfused | Placebo | 2.36 | Standard Deviation 0.81 | Units of packed red blood cells | |
| Number of Participants With a Thromboembolic Event | Tranexamic | 1 | Participants | ||
| Number of Participants With a Thromboembolic Event | Placebo | 0 | Participants | ||
| Estimate Blood Loss | Tranexamic | 727.6 | Standard Deviation 702.52 | mL | |
| Estimate Blood Loss | Placebo | 560.1 | Standard Deviation 378.4 | mL |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 42 | |
| Overall Study | STARTED | Tranexamic | 45 | |
| Overall Study | COMPLETED | Placebo | 42 | |
| Overall Study | COMPLETED | Tranexamic | 45 | |
| Overall Study | NOT COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Tranexamic | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Pulmonary Embolus | Respiratory, thoracic and mediastinal disorders | Tranexamic | 1 | 45 | 1 |
| serious | Pulmonary Embolus | Respiratory, thoracic and mediastinal disorders | Placebo | 0 | 42 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Tranexamic | 0 | 45 |
| Total, all-cause mortality | Placebo | 0 | 42 |
| Total, other adverse events | Tranexamic | 0 | 45 |
| Total, other adverse events | Placebo | 0 | 42 |
| Total, serious adverse events | Tranexamic | 1 | 45 |
| Total, serious adverse events | Placebo | 0 | 42 |
Source ClinicalTrials.gov
Papers38
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Tranexamic vs Placebo: Number of Participants With a Thromboembolic Event | Trial comparisons |
| Tranexamic vs Placebo: Allogenic Blood Transfusion Rates | Trial comparisons |
| Tranexamic vs Placebo: deaths from any cause | Trial comparisons |
| Tranexamic vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02684851
GET https://conductscience.org/api/trials/v1/NCT02684851/papers?page=2